PMID- 36662209 OWN - NLM STAT- MEDLINE DCOM- 20230131 LR - 20240109 IS - 1660-3397 (Electronic) IS - 1660-3397 (Linking) VI - 21 IP - 1 DP - 2022 Dec 31 TI - FTIR Characterization of Sulfated Polysaccharides Obtained from Macrocystis integrifolia Algae and Verification of Their Antiangiogenic and Immunomodulatory Potency In Vitro and In Vivo. LID - 10.3390/md21010036 [doi] LID - 36 AB - The aim of this study was to evaluate the antiangiogenic and immunomodulatory potential of sulfated polysaccharides from the marine algae Macrocystis integrifolia characterized by FTIR. The cytotoxicity of sulfated polysaccharides was evaluated using the 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) assay. Antiangiogenic activity was evaluated using the chicken chorioallantoic membrane (CAM) assay. Immunomodulatory activity was determined on macrophage functionality and allergic response. The results showed that sulfated polysaccharides significantly decreased angiogenesis in chicken chorioallantoic membranes (p < 0.05). Likewise, they inhibited in vivo chemotaxis and in vitro phagocytosis, the transcription process of genes that code the enzymes cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2) and nitric oxide synthase-2 (NOS-2) and the nuclear factor kappa-light chain enhancer of activated B cells (NF-kappaB), showing immunomodulatory properties on the allergic response, as well as an in vivo inhibitory effect in the ovalbumin-induced inflammatory allergy model (OVA) and inhibited lymphocyte proliferation specific to the OVA antigen in immunized mice. Finally, these compounds inhibited the histamine-induced skin reaction in rats, the production of immunoglobulin E (IgE) in mice, and the passive response to skin anaphylaxis in rats. Therefore, the results of this research showed the potential of these compounds to be a promising source for the development of antiangiogenic and immunomodulatory drugs. FAU - Soto-Vasquez, Marilu Roxana AU - Soto-Vasquez MR AUID- ORCID: 0000-0002-1178-4678 AD - Facultad de Farmacia y Bioquimica, Universidad Nacional de Trujillo, Av. Juan Pablo II, Trujillo 13011, Peru. FAU - Alvarado-Garcia, Paul Alan Arkin AU - Alvarado-Garcia PAA AUID- ORCID: 0000-0003-1641-207X AD - Escuela de Medicina, Universidad Cesar Vallejo, Av. Larco s/n, Trujillo 13011, Peru. FAU - Youssef, Fadia S AU - Youssef FS AUID- ORCID: 0000-0002-5871-2639 AD - Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Abbasia, Cairo 11566, Egypt. FAU - Ashour, Mohamed L AU - Ashour ML AUID- ORCID: 0000-0002-9270-6267 AD - Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Abbasia, Cairo 11566, Egypt. AD - Pharmacy Program, Department of Pharmaceutical Sciences, Batterjee Medical College, Jeddah 21442, Saudi Arabia. FAU - Bogari, Hanin A AU - Bogari HA AUID- ORCID: 0000-0001-5974-6235 AD - Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia. FAU - Elhady, Sameh S AU - Elhady SS AUID- ORCID: 0000-0003-3799-0581 AD - Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia. LA - eng GR - Institutional Fund Projects under grant no. (IFPIP:444-249-1443)/This research work was funded by Institutional Fund Projects under grant no. (IFPIP:444-249-1443). The authors gratefully acknowledge technical and financial support provided by the Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi A/ PT - Journal Article DEP - 20221231 PL - Switzerland TA - Mar Drugs JT - Marine drugs JID - 101213729 RN - 0 (NF-kappa B) RN - 0 (Polysaccharides) RN - 0 (Sulfates) RN - 0 (Angiogenesis Inhibitors) RN - 0 (Immunologic Factors) SB - IM MH - Animals MH - Mice MH - Rats MH - *Macrocystis MH - NF-kappa B MH - Polysaccharides/pharmacology MH - Spectroscopy, Fourier Transform Infrared MH - Sulfates MH - Angiogenesis Inhibitors/pharmacology MH - Immunologic Factors/pharmacology PMC - PMC9863126 OTO - NOTNLM OT - Macrocystis integrifolia OT - algae OT - anti-allergic OT - antiangiogenic OT - drug discovery OT - polysaccharides OT - public health COIS- The authors declare no conflict of interest. EDAT- 2023/01/21 06:00 MHDA- 2023/01/25 06:00 PMCR- 2022/12/31 CRDT- 2023/01/20 11:03 PHST- 2022/11/18 00:00 [received] PHST- 2022/12/27 00:00 [revised] PHST- 2022/12/29 00:00 [accepted] PHST- 2023/01/20 11:03 [entrez] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/12/31 00:00 [pmc-release] AID - md21010036 [pii] AID - marinedrugs-21-00036 [pii] AID - 10.3390/md21010036 [doi] PST - epublish SO - Mar Drugs. 2022 Dec 31;21(1):36. doi: 10.3390/md21010036.